Skip to main content
. Author manuscript; available in PMC: 2012 Apr 20.
Published in final edited form as: Bioconjug Chem. 2011 Mar 9;22(4):777–784. doi: 10.1021/bc100584d

Figure 4.

Figure 4

(A) Fluorescence image of LS 573 in 4T1/luc tumor-bearing mouse at indicated times after intravenous administration. Arrows indicate bilateral subcutaneous tumor locations. (B) Plot of average fluorescence intensity values for tumor regions compared with non-tumor control region selected in vivo imaging data. (C) Plot of in vivo tumor contrast at each timepoint showing that high contrast was achieved by 4 h and was maintained for at least 24 h post-injection.